Business Description
Can Fite Biopharma Ltd
ISIN : US13471N3008
Share Class Description:
STU:CF5: ADRTotal Employee Number:
5Compare
Compare
Traded in other countries / regions
CANF.IsraelCANF.USACF5.Germany IPO Date
2019-05-06Description
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 120.23 | |||||
Equity-to-Asset | 0.59 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 2/9 | |||||
Altman Z-Score | -27.17 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -57.9 | |||||
3-Year EBITDA Growth Rate | 47.3 | |||||
3-Year EPS without NRI Growth Rate | 43.3 | |||||
3-Year FCF Growth Rate | 50.2 | |||||
3-Year Book Growth Rate | -49.4 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 354.1 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.46 | |||||
Quick Ratio | 3.46 | |||||
Cash Ratio | 3.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -112.7 | |||||
Shareholder Yield % | -115.54 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -2455.64 | |||||
Net Margin % | -2425.51 | |||||
EBITDA Margin % | -2449.71 | |||||
FCF Margin % | -2214.37 | |||||
OCF Margin % | -2213.79 | |||||
ROE % | -193.82 | |||||
ROA % | -111.87 | |||||
ROIC % | -940.21 | |||||
3-Year ROIIC % | -141.42 | |||||
ROC (Joel Greenblatt) % | -9687.01 | |||||
ROCE % | -153.46 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 0.05 | |||||
PS Ratio | 7.54 | |||||
PB Ratio | 0.91 | |||||
Price-to-Tangible-Book | 0.91 | |||||
EV-to-EBIT | 0.01 | |||||
EV-to-EBITDA | 0.01 | |||||
EV-to-Revenue | -0.2 | |||||
EV-to-Forward-Revenue | 0.06 | |||||
EV-to-FCF | 0.01 | |||||
Price-to-GF-Value | 0.62 | |||||
Price-to-Median-PS-Value | 0.43 | |||||
| Price-to-Net-Current-Asset-Value | 0.92 | |||||
| Price-to-Net-Cash | 1.1 | |||||
Earnings Yield (Greenblatt) % | No Debt | |||||
FCF Yield % | -107.2 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Can Fite Biopharma Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.348 | ||
| EPS (TTM) (€) | -3.23 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | -34.93 | ||
| 3-Year Sortino Ratio | -3.45 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 101 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 101 - 101 | ||
| Shares Outstanding (Mil) | 2.14 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Can Fite Biopharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Can Fite Biopharma Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 130 days | ||
| Second quarter earnings results for 2026 | 2026-08-28 | In 53 days | ||
| First quarter earnings results for 2026 | 2026-07-08 | In 2 days | ||
| General meeting for 2026 | 2026-05-28 15:00 | 101.00 (+0.00%) | ||
| Annual report for 2025 | 2026-03-26 | 101.00 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-26 | 101.00 (+0.00%) | ||
| 0.05:1 Stock Split | 2026-01-05 | 101.00 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-28 | 101.00 (+0.00%) | ||
| General meeting for 2025 | 2025-06-23 12:00 | 101.00 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-04-14 08:00 | 101.00 (+0.00%) |
Show
Entries
Can Fite Biopharma Ltd Frequently Asked Questions
What is Can Fite Biopharma Ltd(STU:CF5)'s stock price today?
The current price of STU:CF5 is €101.00. The 52 week high of STU:CF5 is €101.00 and 52 week low is €101.00.
When is next earnings date of Can Fite Biopharma Ltd(STU:CF5)?
The next earnings date of Can Fite Biopharma Ltd(STU:CF5) is 2026-07-08 Est..
Does Can Fite Biopharma Ltd(STU:CF5) pay dividends? If so, how much?
Can Fite Biopharma Ltd(STU:CF5) does not pay dividend.
Press Release
Articles on Can Fite Biopharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers